RxDoctor Payments Data

Sydney Vangennip, APRN

Family · Sikeston, MONPI 1376252841

Payments from drug & device makers

$1,876in general payments, 2019–2025

Across 95 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$361
  • AstraZeneca$284
  • Boehringer Ingelheim$200
  • AbbVie$133
  • Amgen$126
  • Astellas Pharma US Inc$117
  • plus $656 from 13 others

What the payments were for

  • Food & beverage$1,77695%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,876 in reported general payments places this provider in the 75th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$1,474
Medicare patients
22
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide13$12,089
MyrbetriqMirabegron18$10,365
TradjentaLinagliptin18$9,569
XareltoRivaroxaban14$9,495
LinzessLinaclotide14$8,974
Repatha SureclickEvolocumab13$7,703
Breo ElliptaFluticasone/Vilanterol12$5,120
Duloxetine Hcl13$693
Albuterol Sulfate HfaAlbuterol Sulfate35$592
Atorvastatin Calcium77$587
Torsemide15$551
Losartan Potassium34$411
Omeprazole48$384
Citalopram HbrCitalopram Hydrobromide36$375
Ropinirole Hcl19$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$361$12,08913 claims
Astellas Pharma US IncMyrbetriq$117$10,36518 claims
Boehringer IngelheimTradjenta$200$9,56918 claims
Johnson & JohnsonXarelto$70$9,49514 claims
AbbVieLinzess$133$8,97414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,812 family providers in Missouri.

Other family in Sikeston

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →